One of the most effective treatments in relapsing-remitting MS to date is IFN-β administration that has been used for more than 15 years as a first-line treatment for MS and its efficacy was demonstrated in the setting of EAE [104]. This evidence concerns the gene IFNB1 and myeloid sarcoma.